Development of new anti-cancer drugs constructed with unsaturated alkyl chain
Development of new anti-cancer drugs constructed with unsaturated alkyl chain
批准号:
18590112
负责人:
SUHARA Yoshitomo
金额:
$1.52万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2006
资助国家:
日本
项目状态:
已结题
起止时间:
2006 至 2007
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Our research aim is development of candidates for new anti-cancer drugs based on unsaturated alkyl chain. In this study, we synthesized six kinds of “predictable" vitamin K metabolites. They were introduced vitamin K_2 (menaquinone-2, 3, and 4) molecule to ω-hydroxyl or ω-aldehyde group instead of ω-carboxylic acid becauw the metabolites including ω-carboxylic acid were unstable and unable to use for assay. The requisite analogues were synthesized by coupling the naphthoquinone derivative and side-chain moiety. For the synthesis of side-chain part, we chose geraniol, farnesol and geranylgeraniol as the starting material. While the naphthoquinone part was prepared from 1, 4-diacetoxy-2-methylnaphthoquimne. After coupling reaction, deprotection of protective group gave ω-hydroxyl derivative, and additional oxidative reaction yielded ω-aldehyde derivative. We focused on the apoptosis-inducing activity against HL-60 cells (human leukemia cells). Samples of 5 and 10 μM analogues were succes … More sively added to HL-60 cells. The apoptosis activity was determined with a flow cytemetry. The activity of most analogues increased in a dose-dependent manner. Menaquinone (MK)-3 particularly showed the most potent activity around 75% among vitamin K_2 homologues at 10 μM. On the other hand, the potency of MK-4 was approximately 15%, which equaled 20% of MK-3 at the same dose; however, MK-2 and ω-aldehyde analogues did not exhibit such activity. In terms of ω-oxygenated analogues, ω-oxygenated MK-3 decreased the potency compared to MK-3; however it still preserved about 50% potency of MK-3. Interestingly, only ω-oxygenated MK-4 increased the activity more than substrate MK-4 at 10 μM. Thus, the apoptosis-inducing activity of our analogues as well as natural vitamin K homologues exhibited cell selectivity against cancer cells. Our results indicated that metabolites of vitamin K might have potential as biologically active compounds and can provide useful information to develop new drugs based on vitamin K with modification of terminal alkyl group. Less
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
ビタミンK代謝物を基にした新規誘導体の合成と構造活性相関
基于维生素K代谢物和构效关系的新衍生物的合成
DOI:
--
发表时间:
2007
期刊:
影响因子:
--
作者:
[Suhara Y., Murakami A., Kamao M., Mimatsu S., Nakagawa K., Tsugawa N., Okano T., 須原 義智]
通讯作者:
須原 義智
Synthesis and biological evaluation of vitamin K_2 metabolites.
维生素K_2代谢物的合成及生物学评价。
DOI:
--
发表时间:
2008
期刊:
影响因子:
--
作者:
[Y. Suhara, A. Murakami, M. Kamao, S. Mimatsu, K. Nakagawa, N. Tsugawa, T. Okano]
通讯作者:
T. Okano
Vitamin K Status Is Associated with Vertebral Fracture in Japanese Women
维生素 K 状态与日本女性椎骨骨折有关
DOI:
--
发表时间:
2008
期刊:
J.Bone Miner.Metab. 26(1)
影响因子:
--
作者:
[Y. Fukuyama, et al., 津川 尚子]
通讯作者:
津川 尚子
Efficient Synthesis and Biological Evaluation of w-Oxygenated Analogues of Vitamin K_2:Study of Modification and Structure-activity Relationship of Vitamin K_2 Metabolites
维生素K_2 w-含氧类似物的高效合成及生物学评价:维生素K_2代谢物的修饰及构效关系研究
DOI:
--
发表时间:
2007
期刊:
Bioorg.Med.Chem.Lett. 17
影响因子:
--
作者:
[SUHARA, Y.;MURAKAMI, A.;KAMAO, M.;NAKAGAWA, K.;TSUGAWA, N.;OKANO, T.]
通讯作者:
T.
DOI:
10.1016/j.bmc.2006.06.004
发表时间:
2006-10
期刊:
Bioorganic & medicinal chemistry
影响因子:
3.5
作者:
[Y. Suhara;Aya Murakami;K. Nakagawa;Yukari Mizuguchi;T. Okano]
通讯作者:
Y. Suhara;Aya Murakami;K. Nakagawa;Yukari Mizuguchi;T. Okano
共 24 条
Synthesis of new compounds inducing potent and selective differentiation from neural stem cells into neurons
-
批准号:23590136
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.41万
-
财政年份:2011
-
负责人:SUHARA Yoshitomo
-
依托单位:
Synthesis of new analogues based on fat-soluble vitamins and biological evaluation as therapeutic agents for degenerative disease of the brain
-
批准号:20590113
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.08万
-
财政年份:2008
-
负责人:SUHARA Yoshitomo
-
依托单位: